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To Ask a Question
 Using the Webinar System
 “Click” the Q&A tab at the top left of the webinar tool bar
 “Click”  in the white space
 “Type” your question
 “Click” ask
 On the Phone
 Press Star (*) 1 to enter the queue
 State your name
 Listen for the operator to call your name 
 State your organization and then ask your question
Objectives
At the conclusion of this session, the participant will be able to:
 Discuss revised diagnostic testing for Zika virus infection among 
pregnant women
 Discuss clinical management of pregnant women with confirmed or 
possible Zika virus infection
 Discuss use of a range of contraceptive methods in states, with a focus 
on highly effective methods; and
 Discuss strategies for increasing access and availability to highly 
effective contraception
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Topics to be covered
 Updated Interim Zika Clinical Guidance for Pregnant Women 
– Rationale for changes and updates to testing algorithm
– Additional testing recommendations 
– Clinical management recommendations 
 Pregnancy Planning and Contraception during a Zika Outbreak
– Unintended pregnancy in states potentially affected by Zika
– Data on contraception use in the United States
– Strategies to increase access to and availability of contraception
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Centers for Disease Control and Prevention
Zika Virus & Pregnancy:
CDC’s Updated Interim Guidance 
for Pregnant Women
Titilope Oduyebo, M.D., M.P.H.
August 9, 2016
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Background: Map of Areas with Active Transmission of Zika 
54 countries and 
territories  
worldwide, including 
41 countries and 
territories in the 
Americas, reporting 
active Zika virus 
transmission
As of August 2, 2016
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Local Transmission in the United States
 Florida Department of Health identified mosquito-borne transmission of Zika virus 
in a 1 square mile area of Miami
 CDC released recommendations for travel and testing of pregnant women and 
women of reproductive age who live in or have traveled to this area any time after 
June 15, 2016
 Health Advisory Notice emphasized that this updated interim clinical guidance 
should be applied in the context of active Zika virus transmission in Florida
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Diagnostic Testing for Zika Virus 
 Molecular method
– Real-time reverse transcriptase-polymerase chain reaction (rRT-PCR) 
for viral RNA in body fluids or tissues
 Serologic method
– Zika virus immunoglobulin M (IgM) enzyme-linked immunosorbent 
assay 
– Plaque reduction neutralization test (PRNT) to detect neutralizing 
antibodies in serum 
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Detecting Zika Virus RNA
15
Detecting Zika Virus Antibodies
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Limitations of Zika Tests
 Presence of Zika virus RNA is relatively short-lived and negative results do 
not preclude infection
 Testing for Zika virus IgM can result in false positive results because of 
cross-reacting antibodies against related flaviviruses and for nonspecific 
reasons 
 PRNT levels may not distinguish infecting virus in people previously 
infected with or vaccinated against a related flavivirus
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Rationale for Expanded RT-PCR Testing: 
Prolonged Detection of Zika Virus RNA
 Pregnant woman with Zika virus infection and prolonged detection of Zika virus in serum 
 Case report highlights 
– Detection of ZIKV RNA in serum longer than expected
Driggers, RW, et al., Zika virus infection with prolonged maternal viremia and fetal brain abnormalities. The New England Journal of Medicine, 2016. 374(22):2142-51.
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Prolonged Detection of Zika Virus RNA
 US Zika Pregnancy Registry
– Case series: 5 pregnant women with Zika virus infection reported in 1st or 2nd trimester
• 4 symptomatic (Zika RNA detected 17-46 days after symptom onset)
• 1 asymptomatic (Zika RNA detected 53 days after possible exposure)
 Case series demonstrated that
– Some pregnant women including asymptomatic women may have prolonged detection of 
Zika virus RNA in serum 
– Expanded rRT-PCR testing can provide a definitive diagnosis of Zika virus infection 







Step 1: Assess Exposure and Evaluate Patient 
Assess for possible Zika virus exposure
Evaluate for signs and symptoms of Zika virus disease
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Arm A: Pregnant Women Presenting for Care 
within 2 Weeks of Symptoms or Exposure
IF
 Symptomatic: <2 weeks after 
symptom onset
 Asymptomatic and NOT living in 
an area with active Zika virus 
transmission: <2 weeks after 
possible exposure
Testing indicated
Zika virus rRT-PCR on serum and urine
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Arm A: rRT-PCR Results
Results
Positive Zika virus rRT-PCR on serum or urine
 Recent Zika virus infection
Results
 Negative Zika virus rRT-PCR on serum and urine
Additional testing
 Symptomatic: Zika virus IgM and dengue 
virus IgM
 Asymptomatic and NOT living in an area 
with active Zika virus transmission: Zika 
virus IgM 2-12 weeks after exposure
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Arm A: IgM Results
Results
Zika virus IgM and dengue virus IgM negative
 No evidence of recent Zika virus infection
Results
 Zika virus IgM or dengue virus IgM positive or 
equivocal
Additional testing
 Plaque reduction neutralization test (PRNT)
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Arm A: PRNT Results
Results
Zika virus PRNT ≥ 10 and 
dengue virus PRNT <10
 Recent Zika virus infection
Results
Zika virus PRNT ≥ 10 and 
dengue virus PRNT ≥ 10
 Recent flavivirus infection, 
specific virus cannot be 
identified
Results
Zika virus PRNT < 10
 No evidence of recent Zika
virus infection
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Updated Testing Algorithm: Arm B
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Arm B: Pregnant Women Presenting for Care 
2-12 Weeks after Symptoms or Exposure
IF
 Symptomatic: 2-12 weeks after symptom onset, or
 Asymptomatic and NOT living in an area with active Zika 
virus transmission: 2-12 weeks after possible exposure, or
 Asymptomatic and living in an area with active Zika virus 
transmission: 1st & 2nd trimester
Testing indicated:
Zika virus IgM and dengue virus IgM§ on serum
§ Dengue virus IgM antibody 
testing is recommended only 
for symptomatic pregnant 
women
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Arm B: IgM Results
Results
Dengue virus IgM positive or 
equivocal and Zika virus IgM 
negative
Additional testing:
 Plaque reduction 
neutralization test (PRNT)
Results
Zika virus IgM positive or 
equivocal  and any result on 
dengue virus IgM
Additional testing:
 Reflex Zika virus rRT-PCR on 
serum and urine
Results
Zika virus IgM and dengue 
virus IgM negative
 No evidence of recent Zika 
virus infection
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Arm B : Positive IgM Results Leading to 
rRT-PCR Results
Results
Negative Zika virus reflex rRT-PCR on serum
Additional testing:
 Plaque reduction neutralization test 
(PRNT)
Results
Positive Zika virus rRT-PCR on serum or urine
 Recent Zika virus infection
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Arm B: PRNT Results
Results
Zika virus PRNT ≥ 10 and 
dengue virus PRNT <10
 Recent Zika virus infection
Results
Zika virus PRNT ≥ 10 and 
dengue virus PRNT ≥ 10
 Recent flavivirus infection, 
specific virus cannot be 
identified
Results
Zika virus PRNT < 10
 No evidence of recent Zika
virus infection
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Additional Testing Recommendations 
 For symptomatic and asymptomatic pregnant women who seek care >12 
weeks after symptom onset or possible exposure
– Consider IgM antibody testing 
• If fetal abnormalities are present, also perform rRT-PCR testing
 A negative IgM or rRT-PCR result >12 weeks does not rule out Zika virus 
infection
– Zika virus IgM antibody and RNA levels decrease over time
– Serial fetal ultrasounds should be considered
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Recommendations for Prenatal & Postnatal 
Management of Pregnant Women with Laboratory 
Evidence of Confirmed or Possible Zika Virus Infection
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Prenatal Management: Confirmed or Presumptive 
Recent Zika Virus or Flavivirus Infection
 Serial ultrasounds every 3-4 weeks to assess fetal anatomy and growth
 Amniocentesis 
– Individualized for pregnant women with confirmed recent Zika virus or 
flavivirus infection
– Can be considered for pregnant women with presumptive recent Zika virus or 
flavivirus infection
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 Live births 
– Infant serum should be tested for Zika RNA, Zika IgM, & dengue IgM
• CSF (if obtained for other reasons) 
– Pathology testing by Zika rRT-PCR and/or immunohistochemical staining (IHC) 
of umbilical cord and placenta is recommended
 Fetal loss
– Pathology testing with Zika virus rRT-PCR and/or IHC staining of fetal tissues is 
recommended
Postnatal Management: Confirmed or Presumptive 
Recent Zika Virus or Flavivirus Infection
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Clinical Management: No Evidence of Zika or Dengue
 Prenatal ultrasound to evaluate for fetal abnormalities consistent with congenital 
Zika virus infection
– If fetal ultrasound is
• Abnormal: repeat Zika virus rRT-PCR and IgM antibody tests; clinical 
management should be based on corresponding laboratory results
• Normal: obstetric care should be based on whether pregnant woman has 




 CDC maintains a 24/7 Zika consultation service for health officials and 
healthcare providers caring for pregnant women to assist with test 
interpretation and questions about clinical management
– To contact the service, call 770-488-7100 and ask for the Zika 
Pregnancy Hotline or email ZIKAMCH@cdc.gov
 Healthcare providers should work closely with the state, local, or 
territorial health department to ensure that all appropriate testing will be 
performed.  
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Centers for Disease Control and Prevention
Contraception and Pregnancy Planning  
During a Zika Outbreak




Topics to be Covered: Contraception
 Considerations for women and couples interested in conceiving
 Unintended pregnancy in states potentially affected by Zika
 Contraception to minimize Zika-affected pregnancies
 Contraceptive method effectiveness
 Data on contraception use in the United States
 Strategies to increase access to and availability of long-acting reversible 
contraception (LARC)
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Considerations for Women and Couples Interested in 
Conceiving in the Context of Zika
 Reproductive life plan
 Environmental risk of exposure
 Personal measures to prevent mosquito bites
 Personal measures to prevent sexual transmission
 Education about Zika virus infection during pregnancy
 Risks and benefits of pregnancy at this time
 Delay in conception if either partner infected with Zika virus 
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Tools for Healthcare Providers and Couples Who Want to Conceive
www.cdc.gov/Zika
*Free online materials available to download in English and Spanish
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Preventing Zika-related Outcomes for Women Who 
Choose to Delay or Avoid Pregnancy
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Unintended Pregnancy in States Potentially Impacted by Zika
Dreweke J. Countering Zika Globally and in the United States: Women’s Right to Self-Determination Must Be Central, New York: Guttmacher Policy Review, 2016, 
https://www.guttmacher.org/sites/default/files/article_files/gpr1902316.pdf.
Current contraceptive use in the United States, 2006–2010, and changes in patterns of use since 1995, National Health Statistics Reports, 2012, No. 60.
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Preventing Unintended Pregnancy During a Zika Outbreak
 The best way to reduce risk of unintended pregnancy is to use 
effective birth control consistently and correctly.
 Preventing unintended pregnancy is a primary strategy to prevent 
poor pregnancy and birth outcomes linked to Zika infection during 
pregnancy.
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Contraceptive Counseling during a Zika Virus Outbreak
 Healthcare providers should discuss: 
 Strategies to prevent unintended 
pregnancy
 Use of contraceptive                                           
methods that best meet the needs of 
the woman and/or couple and can be 
used correctly and consistently
 Role of correct and consistent use of                       
condoms and other barrier methods to 
reduce the risk for sexually transmitted 
infections, including Zika
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Client-Centered Approach to Contraceptive Counseling
 Respects the client’s primary purpose for seeking services
 Notes the importance of confidential services 
 Encourages the availability of the full-range of FDA-approved 
contraceptive methods 
 Delivers culturally competent services
Gavin L, Pazol K. Update: Providing Quality Family Planning Services — Recommendations from CDC and the U.S. Office of Population Affairs, 2015. MMWR Morb Mortal Wkly
Rep 2016;65:231–234.
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Highly Effective Contraceptive Methods
 Failure rate: < 1 pregnancy per 100 women each year
 Permanent methods: female sterilization (tubal ligation, transcervical
sterilization), male vasectomy
 Long-acting reversible methods: 
Intrauterine devices (IUDs), contraceptive implants
http://www.cdc.gov/reproductivehealth/unintendedpregnancy/pdf/contraceptive_methods_508.pdf. 
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Long-Acting Reversible Contraception (LARC)
 Most effective type of reversible birth 
control
• Safe 
• No effort after correct insertion 
• Effective for 3-10 years
• Highest rates of satisfaction and 
continuation
• Immediate return to fertility
 Nationally, use of LARC is low 
CDC. U.S. medical eligibility criteria for contraceptive use, 2010. MMWR Recomm Rep 2010;59(No. RR-4):1–86.
Trussell J. Contraceptive failure in the United States. Contraception 2011;83:397–404.
Boulet SL, D’Angelo DV, Morrow B, et al. Contraceptive Use Among Nonpregnant and Postpartum Women at Risk for Unintended Pregnancy, and Female High School Students, in the Context of Zika 
Preparedness — United States, 2011–2013 and 2015. MMWR Morb Mortal Wkly Rep. ePub: 2 August 2016. DOI: http://dx.doi.org/10.15585/mmwr.mm6530e2.
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Moderately Effective Contraceptive Methods
 Failure rate: 6-12 pregnancies per 100 women each year
 Methods: injections, pills, patches, rings, diaphragms
http://www.cdc.gov/reproductivehealth/unintendedpregnancy/pdf/contraceptive_methods_508.pdf
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Less Effective Contraceptive Methods
 Failure rate: ≥ 18 pregnancies per 100 women each year
 Methods: male and female condoms, cervical cap, sponge, withdrawal, 




CDC and State Surveillance of Contraceptive Use
Surveillance System Population Surveyed Data Analyzed
Behavioral Risk Factor 
Surveillance System (BRFSS)
Nonpregnant women aged 18-
44 at risk for unintended 
pregnancy
2011-2013 data from 17 states
Pregnancy Risk Assessment 
Monitoring System (PRAMS)
Postpartum women aged 15-44 
at risk for unintended pregnancy
2013 data from 28 PRAMS states
Maternal and Infant Health
Assessment (MIHA)
Postpartum women at risk for 
unintended pregnancy
2013 data from California
Youth Risk Behavior Surveys 
(YRBS)
Sexually active female students
in grades 9-12
2015 data
http://www.cdc.gov/brfss/, https://www.cdc.gov/prams/, http://www.cdph.ca.gov/data/surveys/MIHA/Pages/MaternalandInfantHealthAssessment(MIHA)survey.aspx, 
http://www.cdc.gov/healthyyouth/data/yrbs/index.htm
57
Contraceptive Use in the United States, 2011-2013 & 2015
 For this analysis
 Less effective contraception: >10 pregnancies per 100 women each year
 Moderately effective contraception: 6-10 pregnancies per 100 women each year
 Contraception use varied across states
 Moderately and less effective methods were used more frequently than 
highly effective methods across all age groups and race/ethnicity.
Trussell J. Contraceptive failure in the United States. Contraception 2011;83:397–404.
Boulet SL, D’Angelo DV, Morrow B, et al. Contraceptive Use Among Nonpregnant and Postpartum Women at Risk for Unintended Pregnancy, and Female High 
School Students, in the Context of Zika Preparedness — United States, 2011–2013 and 2015. MMWR Morb Mortal Wkly Rep. ePub: 2 August 2016. 
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Boulet SL, D’Angelo DV, Morrow B, et al. Contraceptive Use Among Nonpregnant and Postpartum Women at Risk for Unintended Pregnancy, and Female High 
School Students, in the Context of Zika Preparedness — United States, 2011–2013 and 2015. MMWR Morb Mortal Wkly Rep. ePub: 2 August 2016. 
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Barriers to LARC Access and Availability
• High cost
• Limited provider reimbursement
• Training
• Lack of awareness about LARC methods
• Cultural and other factors
CDC’s 6|18 Initiative: Evidence Summary to Prevent Unintended Pregnancy. CDC, Atlanta, GA http://www.cdc.gov/sixeighteen/docs/6-18-evidence-summary-pregnancy.pdf.
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Strategies to Improve LARC Access and Availability
Barriers Strategies
High cost
• Remove administrative barriers for contraceptive services and supplies
• Partner with health system payers to implement contraceptive services
Limited provider 
reimbursement
• Reimburse for the full range of contraceptive services
Training
• Increase healthcare provider training on insertion and removal techniques
• Improve same-day access to services by removing non-essential requirements
Lack of awareness about 
LARC methods
• Provide client-centered contraceptive counseling on the full range of FDA-approved 
birth control methods
• Increase awareness of LARC methods to all clients
Cultural and other 
factors
• Provide youth-friendly, culturally appropriate services during visits




CDC’s6|18 Initiative: Evidence Summary to Prevent Unintended Pregnancy. CDC, Atlanta, GA http://www.cdc.gov/sixeighteen/docs/6-18-evidence-summary-pregnancy.pdf
http://www.astho.org/Programs/Maternal-and-Child-Health/Long-Acting-Reversible-Contraception-LARC/
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For more information, contact CDC
1-800-CDC-INFO (232-4636)
TTY:  1-888-232-6348    www.cdc.gov
The findings and conclusions in this report are those of the authors and do not necessarily represent the 
official position of the Centers for Disease Control and Prevention.
Thanks to our many collaborators and partners!
For clinical questions, please contact
ZikaMCH@cdc.gov
For US Zika Pregnancy Registry questions, please contact
ZikaPregnancy@cdc.gov
To Ask a Question
 Using the Webinar System
 “Click” the Q&A tab at the top left of the webinar tool bar
 “Click”  in the white space
 “Type” your question
 “Click” ask
 On the Phone
 Press Star (*) 1 to enter the queue
 State your name
 Listen for the operator to call your name 
 State your organization and then ask your question
Thank you for joining!
Please email us questions at coca@cdc.gov
Centers for Disease Control and Prevention 
Atlanta, Georgia
http://emergency.cdc.gov/coca 
Continuing Education for COCA Calls
Continuing Education guidelines require that the attendance of all who 
participate in COCA Conference Calls be properly documented. All Continuing 
Education credits/contact hours (CME, CNE, CEU, CECH, ACPE and 
AAVSB/RACE) for COCA Conference Calls/Webinars are issued online through 
the CDC Training & Continuing Education Online system 
(http://www.cdc.gov/TCEOnline/).
Those who participate in the COCA Conference Calls and who wish to receive 
CE credit/contact hours and will complete the online evaluation by June 4, 
2016 will use the course code WC2286. Those who wish to receive CE 
credits/contact hours and will complete the online evaluation between June 
5, 2016 and June 4, 2017 will use course code WD2286. CE certificates can be 
printed immediately upon completion of your online evaluation. A cumulative 
transcript of all CDC/ATSDR CE’s obtained through the CDC Training & 
Continuing Education Online System will be maintained for each user. 
Upcoming COCA Call
CDC Guideline for Prescribing Opioids for 
Chronic Pain: Dosing and Titration of Opioids 
(final call in a series of 4)
Date: Wednesday, August 17, 2016
Time: 2:00 – 3:00 pm (Eastern Time)
Free Continuing Education. Registration Not Required
http://emergency.cdc.gov/coca
Join Us on Facebook
CDC Facebook page for 
clinicians! “Like” our 
page today to learn 
about upcoming COCA 
Calls, CDC guidance 
and recommendations, 
and about other health 
alerts
CDC Clinician Outreach and Communication Activity
https://www.facebook.com/CDCClinicianOutreachAndCommunicationActivity
